Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2021-12-06 00:00:00 ET · period of report 2021-12-03 · accession 0001883850-21-000018 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-06 | 2021-12-03 | REGN | STAHL NEIL | EVP Research, Development | M - OptEx | $179.13 | +72.5K | 101.3K | +252% | +$12.99M |
| DI | 2021-12-06 | 2021-11-29 | REGN | STAHL NEIL | EVP Research, Development | G - Gift | $0.00 | +4,605 | 4,605 | New | $0 |
| D | 2021-12-06 | 2021-11-29 | REGN | STAHL NEIL | EVP Research, Development | G - Gift | $0.00 | -4,605 | 28.8K | -14% | $0 |
| D | 2021-12-06 | 2021-12-03 | REGN | STAHL NEIL | EVP Research, Development | F - Tax | $632.45 | -50.4K | 51.0K | -50% | -$31.85M |
| D | 2021-12-06 | 2021-12-03 | REGN | STAHL NEIL | EVP Research, Development | M - OptEx | $0.00 | -72.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-03 | M | A | 72,500 | $179.13 | 101,309 | D | — | — | |
| 2 | Common | Common Stock | 2021-11-29 | G | A | 4,605 | $0.00 | 4,605 | I | — | — | |
| 3 | Common | Common Stock | 2021-11-29 | G | D | 4,605 | $0.00 | 28,809 | D by Spouse as Trustee | — | — | |
| 4 | Common | Common Stock | 2021-12-03 | F | D | 50,352 | $632.45 | 50,957 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2021-12-03 | M | D | 72,500 | $0.00 | 0 | D | $179.13 · — to 2022-12-14 | 72,500 Common Stock | (F1) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |